Review



cal33 human head  (DSMZ)


Bioz Verified Symbol DSMZ is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    DSMZ cal33 human head
    Sunitinib treatment enhances de novo serine metabolism across multiple cancer models. A, Immunoblots various cancer lines, including 786-O (ccRCC), BT549 (TNBC), A549 (lung), DAOY (medulloblastoma), and <t>Cal33</t> (head and neck), treated with DMSO (veh) or sunitinib (sun; 2.5 μmol/L) for 48 hours. B, Cell count measurements conducted 96 hours after treating BT549, A549, DAOY, and Cal33 with DMSO (veh), sunitinib (2.5 μmol/L), NCT-503 (NCT; 30 μmol/L), or a combination of both treatments. Three different experiments were conducted. ns, nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 (two-way ANOVA).
    Cal33 Human Head, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 104 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cal33 human head/product/DSMZ
    Average 95 stars, based on 104 article reviews
    cal33 human head - by Bioz Stars, 2026-04
    95/100 stars

    Images

    1) Product Images from "De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma"

    Article Title: De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma

    Journal: Cancer Research

    doi: 10.1158/0008-5472.CAN-24-1393

    Sunitinib treatment enhances de novo serine metabolism across multiple cancer models. A, Immunoblots various cancer lines, including 786-O (ccRCC), BT549 (TNBC), A549 (lung), DAOY (medulloblastoma), and Cal33 (head and neck), treated with DMSO (veh) or sunitinib (sun; 2.5 μmol/L) for 48 hours. B, Cell count measurements conducted 96 hours after treating BT549, A549, DAOY, and Cal33 with DMSO (veh), sunitinib (2.5 μmol/L), NCT-503 (NCT; 30 μmol/L), or a combination of both treatments. Three different experiments were conducted. ns, nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 (two-way ANOVA).
    Figure Legend Snippet: Sunitinib treatment enhances de novo serine metabolism across multiple cancer models. A, Immunoblots various cancer lines, including 786-O (ccRCC), BT549 (TNBC), A549 (lung), DAOY (medulloblastoma), and Cal33 (head and neck), treated with DMSO (veh) or sunitinib (sun; 2.5 μmol/L) for 48 hours. B, Cell count measurements conducted 96 hours after treating BT549, A549, DAOY, and Cal33 with DMSO (veh), sunitinib (2.5 μmol/L), NCT-503 (NCT; 30 μmol/L), or a combination of both treatments. Three different experiments were conducted. ns, nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 (two-way ANOVA).

    Techniques Used: Western Blot, Cell Counting



    Similar Products

    cal33 human head  (DSMZ)
    95
    DSMZ cal33 human head
    Sunitinib treatment enhances de novo serine metabolism across multiple cancer models. A, Immunoblots various cancer lines, including 786-O (ccRCC), BT549 (TNBC), A549 (lung), DAOY (medulloblastoma), and <t>Cal33</t> (head and neck), treated with DMSO (veh) or sunitinib (sun; 2.5 μmol/L) for 48 hours. B, Cell count measurements conducted 96 hours after treating BT549, A549, DAOY, and Cal33 with DMSO (veh), sunitinib (2.5 μmol/L), NCT-503 (NCT; 30 μmol/L), or a combination of both treatments. Three different experiments were conducted. ns, nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 (two-way ANOVA).
    Cal33 Human Head, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cal33 human head/product/DSMZ
    Average 95 stars, based on 1 article reviews
    cal33 human head - by Bioz Stars, 2026-04
    95/100 stars
    		  Buy from Supplier
    human head and neck cancer cell line cal33  (DSMZ)
    90
    DSMZ human head and neck cancer cell line cal33
    Sunitinib treatment enhances de novo serine metabolism across multiple cancer models. A, Immunoblots various cancer lines, including 786-O (ccRCC), BT549 (TNBC), A549 (lung), DAOY (medulloblastoma), and <t>Cal33</t> (head and neck), treated with DMSO (veh) or sunitinib (sun; 2.5 μmol/L) for 48 hours. B, Cell count measurements conducted 96 hours after treating BT549, A549, DAOY, and Cal33 with DMSO (veh), sunitinib (2.5 μmol/L), NCT-503 (NCT; 30 μmol/L), or a combination of both treatments. Three different experiments were conducted. ns, nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 (two-way ANOVA).
    Human Head And Neck Cancer Cell Line Cal33, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human head and neck cancer cell line cal33/product/DSMZ
    Average 90 stars, based on 1 article reviews
    human head and neck cancer cell line cal33 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    cal33 human head and neck cancer cell line  (DSMZ)
    90
    DSMZ cal33 human head and neck cancer cell line
    Sunitinib treatment enhances de novo serine metabolism across multiple cancer models. A, Immunoblots various cancer lines, including 786-O (ccRCC), BT549 (TNBC), A549 (lung), DAOY (medulloblastoma), and <t>Cal33</t> (head and neck), treated with DMSO (veh) or sunitinib (sun; 2.5 μmol/L) for 48 hours. B, Cell count measurements conducted 96 hours after treating BT549, A549, DAOY, and Cal33 with DMSO (veh), sunitinib (2.5 μmol/L), NCT-503 (NCT; 30 μmol/L), or a combination of both treatments. Three different experiments were conducted. ns, nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 (two-way ANOVA).
    Cal33 Human Head And Neck Cancer Cell Line, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cal33 human head and neck cancer cell line/product/DSMZ
    Average 90 stars, based on 1 article reviews
    cal33 human head and neck cancer cell line - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Sunitinib treatment enhances de novo serine metabolism across multiple cancer models. A, Immunoblots various cancer lines, including 786-O (ccRCC), BT549 (TNBC), A549 (lung), DAOY (medulloblastoma), and Cal33 (head and neck), treated with DMSO (veh) or sunitinib (sun; 2.5 μmol/L) for 48 hours. B, Cell count measurements conducted 96 hours after treating BT549, A549, DAOY, and Cal33 with DMSO (veh), sunitinib (2.5 μmol/L), NCT-503 (NCT; 30 μmol/L), or a combination of both treatments. Three different experiments were conducted. ns, nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 (two-way ANOVA).

    Journal: Cancer Research

    Article Title: De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma

    doi: 10.1158/0008-5472.CAN-24-1393

    Figure Lengend Snippet: Sunitinib treatment enhances de novo serine metabolism across multiple cancer models. A, Immunoblots various cancer lines, including 786-O (ccRCC), BT549 (TNBC), A549 (lung), DAOY (medulloblastoma), and Cal33 (head and neck), treated with DMSO (veh) or sunitinib (sun; 2.5 μmol/L) for 48 hours. B, Cell count measurements conducted 96 hours after treating BT549, A549, DAOY, and Cal33 with DMSO (veh), sunitinib (2.5 μmol/L), NCT-503 (NCT; 30 μmol/L), or a combination of both treatments. Three different experiments were conducted. ns, nonsignificant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 (two-way ANOVA).

    Article Snippet: CAL33 human head and neck squamous cell carcinoma cells, a human head and neck cancer cell line, was purchased from DSMZ (HTB-186, RRID:CVCL_1108).

    Techniques: Western Blot, Cell Counting